The PEAK ATP ingredient won the award for original clinical research at a conference organized by the Scripps Center earlier this month. 'Natural Supplements: An Evidence-Based Update' aims to raise awareness and the credibility of herbal and natural remedies among doctors.
The firm's small clinical trial provided evidence that a single oral dose of PEAK ATP (adenosine triphosphate) increased peripheral perfusion pressure and oxygenation in healthy men and women, indicating the ingredient may be an effective treatment for patients with peripheral arterial disease (PAD), the most common manifestation of systemic atherosclerosis.
The prize was based on trial design, originality, and potential for future application.
Technical Sourcing claims that its product, produced through fermentation, is the first legitimate ATP supplement on the market and the only one with clinical evidence of efficacy. The company gained the rights to a number of ATP patents developed Dr Eliezer Rapaport, a leading expert on ATP, during 2003.
Researchers at the Minnesota Applied Research Center (MARC) recruited 12 healthy men and women with a mean age of 49.7 years to participate in the study. Each subject was administered three treatments over the course of three one-hour visits - placebo, PEAK ATP 100 mg and PEAK ATP 250 mg.
They were randomized to receive each treatment in a crossover study design with a seven-day washout period between treatments. Arterial systolic pressure, pulse measurements of arterial blood oxygen saturation, and electrocardiogram were obtained at baseline, as well as one hour before and one hour after administration of the test substance.
PEAK ATP administration effectively increased upper and lower extremity perfusion pressure as well as upper extremity oxygenation, reported the company.
The researchers concluded that "oral administration of ATP may be a safe and effective treatment to increase peripheral perfusion pressure and oxygenation in patients with PAD"..
The abstract will be published in the Journal of Complementary and Alternative Medicine. A full-length publication of the trial results is expected later this year.
The conference took place January 7-9 in San Diego.